Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The study will assess the corrected QT (QTc) effects (electrocardiogram [ECG]) of BL-8040
1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single
subcutaneous (SC) injection relative to placebo in approximately 40 healthy subjects.